Date:2/22/2010

n of ($131,330). (5) To exclude additional interest expense as a result of adopting ASC 470-20 of $4,114 and to exclude amortization of the premium on debt acquired from Indevus of ($94). (6) To exclude changes in fair value of financial instruments, net. (7) To reflect the cash tax savings resulting from the Indevus acquisition and the tax effect of the pre-tax adjustments above at applicable tax rates. Three Months Ended Dec. 31, 2008 Actual (unaudited) Reported (GAAP) Adjustments Adjusted -------- ----------- -------- Total Revenues $347,336 - $347,336 Costs and expenses: Cost of revenues 76,681 (8,877) (1) 67,804 Selling, general and administrative 130,288 - 130,288 Research and development 27,967 (6,910) (2) 21,057 Purchased in-process research & development (530 ) 530 (3) - Operating income 112,930 15,257 128,187 Interest (income) expense, net 2,185 (3,752) (4) (1,567) Other (income) expense, net 2,588 (3,320) (5) (732) Income before income taxes 108,157 22,329 130,486 Income taxes 35,471 8,912 (6) 44,383 Net income $72,686 $13,417 $86,103 Diluted earnings per share $0.62 $0.74 Diluted weighted average shares 116,894 116,894 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of ope
'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate